Life Scientist > Lab Technology

Deakin Uni opens bionanotechnology centre in India

02 December, 2010 by Staff Writers

Deakin University and The Energy and Resources Institute of India (TERI) have partnered to open a new bionanotechnology Research Centre in Delhi.


Opinion: Private member's bill on patenting of biological materials seeks to trick and confuse with semantics

29 November, 2010 by Staff Writers

Ian Rourke, Karin Innes and Danielle Burns from patent attorneys FB Rice & Co argue that the recently introduced private member's bill on biological patents is ill thought-out.


Government to review role played by IP in private sector / PFRO collaborations

29 November, 2010 by Staff Writers

The Advisory Council of Intellectual Property (ACIP) is calling for submissions from Australian companies which have collaborated with publicly-funded research organisations (PFROs) as part of a review as to whether intellectual property (IP) rights such as patents and trademarks are a help or a hindrance.


Market report: Biotechs up for third week in a row

27 November, 2010 by David Binning

The S&P/ASX 200 Heathcare Index closed in the black on Friday for the third week in a row, as the wider market slipped for the second week in a row.


R&D Tax Credit bill passes lower house

22 November, 2010 by David Binning

Like a spent fighter coming back from the brink after teetering on the ropes in the dying stages, the federal government’s R&D Tax Credit bill is still standing at the 12th round bell with only one more round to go.


Professor Frank Fenner dies aged 95

22 November, 2010 by Staff Writers

Australian scientists today paid tribute to the distinguished life and career of Professor Frank Fenner AC, MBE who passed away today aged 95.


Opinion: Business hit by R&D Tax Credit uncertainty

17 November, 2010 by Staff Writers

Twelve months after the release of the initial draft of the R&D Tax Credit, a series of false starts, contested claims and last minute legislative changes have seen the proposed 1 July 2010 start date come and go, with no resolution to the confusion in sight.


Market report: Aussie biotechs defy wider market blues

13 November, 2010 by David Binning

The S&P/ASX 200 Heathcare Index managed to sneak into positive territory this week, adding to last week’s strong gains.


Avexa to buy 24 percent of Allied Medical

12 November, 2010 by David Binning

Troubled HIV treatment developer Avexa will pay around $1.5 million to acquire up to 24 percent of Western Australia medical devices company Allied Medical under the terms of a deal revealed this week.


What is the R&D Tax Credit?

10 November, 2010 by Tim Dean

The R&D Tax Credit legislation has had a chequered past, going through multiple revisions and stalling before entering the Senate prior to the federal election.


Government names ‘experts’ to chart course for enabling technologies

05 November, 2010 by Staff Writers

The federal government has named the 21-strong expert advisory panel who will help chart the direction of its $38.2 million National Enabling Technologies Strategy.


Government announces $160 million for four new innovation funds

05 November, 2010 by Staff Writers

The federal government today announced the formation of four new funds with a combined war chest of $160 million to support Australian innovation.


Australia and China to build new nanotechnology lab

05 November, 2010 by David Binning

The governments of Australia and China have announced that they will jointly fund a new state-of-the-art nanotechnology laboratory in China.


Applications open for 14th round of CRCs

03 November, 2010 by Staff Writers

Federal innovation Minister Senator Kim Carr today announced the opening of round 14 of the CRC ( cooperative research centres) program, inviting companies around Australia to partner up and submit their applications for funding.


Aussie biotech equities under perform wider market for Q1: PWC

28 October, 2010 by Staff Writers

PricewaterhouseCoopers has released its Q1FY11 BioForum report on Australia’s life sciences and biotech equities, revealing that the sector went backwards slightly as the wider market advanced.


  • All content Copyright © 2022 Westwick-Farrow Pty Ltd